Ubix Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Ubix Therapeutics, Inc. - overview
Established
2018
Location
Seoul, -, South Korea
Primary Industry
Biotechnology
About
Founded in 2018 and based in Seoul, South Korea, Ubix Therapeutics is a pharmaceutical research and development company specializing in the technology known as Proteolysis Targeting Chimera (PROTAC), which is an inhibitor cell technology to treat cancer and intractable disease. In March 2023, Ubix Therapeutics raised KRW 12 billion in series C funding from new investors Scale Up Partners, QUAD Ventures, Medytox Venture Investment, GeneN Investment Partners, and BNH Investment. Returning investors UTC Investment, Mirae Asset Venture Investment, and Atinum Investment also participated in this round. As of 2023, the company is led by its CEO Bo-Kwang Seo.
The company offers research and development of new drug services.
Current Investors
Mirae Asset Venture Investment, Premier Partners, Korea Development Bank
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.ubixtrx.com/
Company Stage
Series C
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.